DEF: Tempest Therapeutics Special Meeting on Share Issuance

Tempest Therapeutics is holding a special meeting on June 18, 2026, to seek stockholder approval for the issuance of shares related to warrant exercises, crucial for Nasdaq compliance and company operations.

Summary

• Tempest Therapeutics, Inc. is convening a Special Meeting of Stockholders on June 18, 2026, at 12:00 p.m. Eastern Time, to be held virtually.
• The primary purpose of the meeting is to obtain stockholder approval for two proposals related to the issuance of common stock upon the exercise of warrants.
• Proposal 1 seeks approval for the issuance of up to 925,927 shares of common stock upon exercise of Series A and Series B Warrants, issued in connection with a private placement on March 20, 2026.
• Proposal 2 seeks approval for the issuance of up to 2,344,828 shares of common stock upon exercise of Common Warrants, issued as part of an inducement offer on May 28, 2026.
• These approvals are required to comply with Nasdaq Listing Rule 5635, which mandates stockholder approval for certain share issuances, particularly when they represent 20% or more of outstanding stock or are issued at a discount to market value.
• The meeting will be conducted virtually, accessible via www.virtualshareholdermeeting.com/TPST2026SM, with online check-in starting 15 minutes prior.
• The record date for determining stockholders entitled to vote is May 28, 2026.
• The Board of Directors unanimously recommends a vote in favor of both proposals.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a procedural proxy statement focused on corporate governance and Nasdaq compliance rather than operational or financial performance updates.

Positives

• The company is proactively seeking stockholder approval to comply with Nasdaq listing rules, demonstrating a commitment to corporate governance.
• Approval of the proposals is crucial for the company's liquidity and operational funding, as it relates to capital raised through warrant exercises.
• The virtual meeting format allows for broader stockholder participation regardless of location.
• The Board of Directors unanimously supports both proposals, indicating management's confidence in these transactions.

Negatives

• Failure to obtain stockholder approval for Proposal 1 could lead to repeated meetings every 90 days, increasing administrative expenses.
• Failure to obtain stockholder approval for Proposal 2 could jeopardize future financing prospects, as potential investors might view stockholders as unsupportive.
• The issuance of shares upon warrant exercise could potentially dilute existing shareholders' ownership.
• The sale of shares into the public market underlying these warrants could materially and adversely affect the market price of the company's common stock.

Risks

• The potential sale of a significant number of shares into the public market following warrant exercises could negatively impact the stock price.
• Failure to secure stockholder approval for the warrant issuances could lead to increased G&A expenses due to repeated meeting requirements and could jeopardize future financing.
• The company is subject to Nasdaq listing rules, and non-compliance could have implications.

Future Outlook

The company is seeking stockholder approval to issue shares upon the exercise of warrants, which is critical for meeting Nasdaq requirements and supporting its liquidity and operations. Failure to gain approval could lead to increased expenses and jeopardize future financing.

Management Comments

• The Board of Directors unanimously recommends a vote in favor of Proposal 1.
• The Board of Directors unanimously recommends a vote in favor of Proposal 2.
• The company is seeking stockholder approval to comply with Nasdaq Listing Rule 5635(c) and (d).

Industry Context

StockSavvy.ai notes that seeking stockholder approval for significant share issuances, especially those potentially dilutive or issued below market value, is a common requirement under Nasdaq rules to protect existing shareholders and maintain market integrity. Companies often hold special meetings for such purposes.

Corporate Governance

Related Party Transactions

• Dr. Matthew Angel, CEO and director, is a majority equityholder of the parent of Factor Bioscience Inc., which is an investor in the private placement and will receive shares upon exercise of Series A and Series B Warrants (Proposal 1).

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of shares upon warrant exercise. Their vote is critical for the company's compliance and financial stability.
• Management: Responsible for ensuring Nasdaq compliance and securing necessary approvals.
• Investors: The outcome of the vote will impact the company's ability to fund operations and its future financing prospects.

Next Steps

• Stockholders to vote on Proposal 1 and Proposal 2 at the Special Meeting on June 18, 2026.
• If approved, shares will be issuable upon exercise of the Series A, Series B, and Inducement Warrants.
• If Proposal 1 is not approved, the company may be required to hold subsequent meetings every 90 days.
• If Proposal 2 is not approved, the company may be required to hold subsequent meetings every 90 days.
• Final voting results will be published in a Form 8-K within four business days after the Special Meeting.

Key Dates

Recommendation

This filing is a procedural proxy statement for a special meeting to approve warrant issuances, not an indicator of current financial performance or strategic shifts. While management recommends approval, the potential for dilution and the need for further capital raises suggest a 'hold' stance pending more substantive operational or financial updates.

Keywords

Tempest Therapeutics, Special Meeting, Stockholder Approval, Warrants, Share Issuance, Nasdaq Compliance, Proxy Statement, DEF 14A, Private Placement, Inducement Offer